44 results on '"Schönland, Stefan"'
Search Results
2. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
3. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
4. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
5. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
6. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
7. Leichtkettenamyloidose
8. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
9. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
10. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
11. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
12. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
13. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
14. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
15. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
16. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
17. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
18. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
19. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
20. Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
21. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
22. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
23. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril
24. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)
25. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
26. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
27. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis
28. Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis
29. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
30. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis
31. Neuere pharmakologische Interventionen bei Leichtketten-Amyloidose
32. AL amyloidosis with a localized B cell neoplasia
33. Deferred autologous stem cell transplantation in systemic AL amyloidosis
34. Systemic immunoglobulin light chain amyloidosis
35. Local vs. systemic pulmonary amyloidosis—impact on diagnostics and clinical management
36. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
37. Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis
38. Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre
39. Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients
40. Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy
41. MR-Neurography of the sural nerve in patients with hereditary amyloidosis
42. Treatment of cardiac AMyloid light-chain amyloidosis with the green tea compound Epigallocatechin-3-gALlate (TAME-AL)
43. Amyloid in endomyocardial biopsies
44. Three German fibrinogen Aα-chain amyloidosis patients with the p.Glu526Val mutation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.